Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Astex Pharmaceuticals Announces Initiation of SGI-110 Phase II Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

FDAnews Drug Daily Bulletin

Oct. 3, 2012 | Vol. 9 No. 194

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase II Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

Astex Pharmaceuticals announced that it has initiated a Phase II, open label, randomized, multi-center, controlled clinical trial, evaluating SGI-110 in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients.
NASDAQ

Register Now
Print This Page
Email This Article
RSS
Archives

Mylan Launches Generic Tricor Tablets Is the FDA Approving too Many Drugs Starting with X and Z?Court Rejects Merck Deal Over Vioxx Citizens in Poor EU States Can’t Afford Medicines, Health Promoters Say

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.